- Home
- IMCR vs BBAR Comparison
IMCR vs BBAR Comparison
Compare IMCR & BBAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BBAR
- Stock Information
- Founded
- IMCR 2008
- BBAR 1886
- Country
- IMCR United Kingdom
- BBAR Argentina
- Employees
- IMCR N/A
- BBAR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BBAR Commercial Banks
- Sector
- IMCR Health Care
- BBAR Finance
- Exchange
- IMCR Nasdaq
- BBAR Nasdaq
- Market Cap
- IMCR 1.6B
- BBAR 3.4B
- IPO Year
- IMCR 2021
- BBAR N/A
- Fundamental
- Price
- IMCR $35.00
- BBAR $14.65
- Analyst Decision
- IMCR Buy
- BBAR Buy
- Analyst Count
- IMCR 10
- BBAR 1
- Target Price
- IMCR $58.13
- BBAR $27.00
- AVG Volume (30 Days)
- IMCR 383.2K
- BBAR 645.0K
- Earning Date
- IMCR 08-07-2025
- BBAR 08-20-2025
- Dividend Yield
- IMCR N/A
- BBAR 6.67%
- EPS Growth
- IMCR N/A
- BBAR 9.91
- EPS
- IMCR N/A
- BBAR 0.57
- Revenue
- IMCR $333,581,000.00
- BBAR $2,595,064,489.00
- Revenue This Year
- IMCR $26.82
- BBAR N/A
- Revenue Next Year
- IMCR $8.15
- BBAR $35.30
- P/E Ratio
- IMCR N/A
- BBAR $9.00
- Revenue Growth
- IMCR 25.75
- BBAR N/A
- 52 Week Low
- IMCR $23.15
- BBAR $7.05
- 52 Week High
- IMCR $41.54
- BBAR $25.01
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- BBAR 31.25
- Support Level
- IMCR $32.20
- BBAR $15.35
- Resistance Level
- IMCR $35.75
- BBAR $16.59
- Average True Range (ATR)
- IMCR 1.31
- BBAR 0.74
- MACD
- IMCR 0.28
- BBAR -0.06
- Stochastic Oscillator
- IMCR 84.94
- BBAR 0.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.